Enzymotec Ltd. announced that it has filed a registration statement on Form F-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Enzymotec has applied to list its ordinary shares on the Nasdaq Global Market under the ticker symbol "ENZY."

BofA Merrill Lynch and Jefferies LLC will act as joint book-running managers for the proposed offering. Wells Fargo Securities, LLC will act as lead manager for the proposed offering. Canaccord Genuity and Wedbush Securities will act as co-managers for the proposed offering.

The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus relating to the offering may be obtained from either: BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attention: Prospectus Department or emailing [email protected]; or Jefferies LLC, 520 Madison Ave, 12th Floor, New York, NY 10022, 877-547-6340, email: [email protected].

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the registration statement becomes effective.